Allozyne, the Seattle-based developer of protein drugs, is announcing today it has obtained a license from Sigma-Aldrich (NASDAQ: [[ticker:SIAL]]) to chemical technology for linking certain compounds to protein drugs. Terms of the license to Sigma’s cycloaddition technology weren’t disclosed, although it covers drug and diagnostic uses that Allozyne may pursue in the future. Allozyne didn’t say what it plans to do with the license, although it has said it intends to make protein drugs last longer in the bloodstream and require fewer injections, or specifically hit more than one biological target. This is the second deal that Allozyne has struck to help it alter protein drugs, after the company said last month it had obtained rights to “click chemistry” technology from The Scripps Research Institute in San Diego.
